Introduction

B cell chronic lymphocytic leukemia (CLL) is characterized by the accumulation of monoclonal CD5
+ B cells in blood, secondary lymphoid tissues, and the bone marrow 1 .
Most of the circulating leukemia cells are arrested in the G o /G 1 phase of the cell cycle, and therefore the primary defect may be one of resistance to apoptosis rather than accelerated cell division 2 . However, in vitro CLL cells undergo spontaneous apoptosis, suggesting that such ex vivo conditions lack factors necessary for leukemia-cell survival and that the resistance to apoptosis is not intrinsic to the leukemia B cell. In vitro apoptosis of CLL cells can be prevented by co-culture with different accessory cells that are part of the CLL microenvironment, such as monocyte-derived nurselike cells [3] [4] [5] [6] , mesenchymal marrow stromal cells (MSC) 3, 7, 8 , or follicular dendritic cells (FDC) 9 that provide survival signals to CLL cells. NLC differentiate from monocytes into large, round, adherent cells that attract CLL cells and protect them from undergoing spontaneous or drug-induced cell death in a contact-dependent fashion 3, 4, 10 . Because these cells share features in common with thymic nurse cells that nurture developing thymocytes 11 , we designated these cells "nurselike cells," or NLC 3 . NLC can be found in the spleen and secondary lymphoid tissue of patients with CLL 4 and thus represent a model for the microenvironment in secondary lymphatic tissues. High levels of CD68 makes NLC comparable to CD68 + lymphoma-associated macrophages (LAM) in follicular lymphoma (FL) 12 . Although still controversial, some studies demonstrated that a high CD68 + cell content in the microenvironment is associated with an aggressive clinical course and poor outcome in FL [12] [13] [14] , suggesting that cell-cell interactions between the lymphoma cells and accessory cells of monocyte/macrophage lineage play a role in supporting neoplastic B cell growth and drug resistance in lymphatic tissues. In addition, T cells are an integral part of the microenvironment in CLL. In CLL pseudofollicles (PF), CLL cells are interspersed with T cells in proliferation clusters 15, 16 . PF are a hallmark finding in CLL histopathology and are considered the proliferative compartment of this disease 17- only.
For personal use at PENN STATE UNIVERSITY on . bloodjournal.hematologylibrary.org From 4 19 . In PF, T cells are in intimate contact with CLL cells, and express activation markers, such as CD40 ligand (CD154) 15, 20 . Moreover, contact with activated CD4 + T cells induces Survivin 15 and CD38 expression 16 in CLL cells in PF, suggesting that T cells promote CLL cell activation and proliferation in these areas 16, 17 . However, the factors promoting co-localization of T cells with CLL cells are largely unknown 16 .
Several molecules involved in cross talk between CLL cells and their microenvironment have recently been identified based upon in vitro work and correlative studies on CLL tissue specimen. We characterized CXCL12 (SDF-1), a chemokine constitutively secreted by MSC 21 and NLC 3 , as a chemotactic and anti-apoptotic factor for CLL cells, acting through its cognate receptor termed CXCR4, which is expressed at high levels on CLL cells 21, 22 . CXCR4 antagonists make CLL cells susceptible to chemotherapeutic drugs in stroma co-cultures 10, 23 , and we therefore proposed the CXCL12-CXCR4 axis as a therapeutic target in CLL 3, 10 . However, our initial 3 and a subsequent study 6 indicated that the CXCR4-CXCL12 axis is not the only pro-survival pathway in CLL-NLC cross talk 10, 23 . More recently, we reported that NLC express another chemokine called CXCL13 which binds to CXCR5 chemokine receptors expressed at high levels on CLL cells 24, 25 . Similar to CXCL12, CXCL13 is another homeostatic chemokine constitutively secreted by stromal cells in B cell follicles which recruits circulating B cells to follicles 26, 27 . In addition to CXCL12 and CXCL13, NLC express B cell-activating factor of the tumor necrosis factor (TNF) family (BAFF), a proliferation-inducing ligand (APRIL) 6 , CD31, and plexin-B1 5 that also protect CLL cells from apoptosis, indicating that NLC use multiple distinct pathways to support CLL cell survival. 
Material and Methods
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Expression analysis
Gene expression studies were performed using HG U133 plus 2.0 oligonucleotide arrays from Affymetrix (Affymetrix, Santa Clara, CA). The samples were processed following the protocol for eukaryotic samples in the expression analysis technical manual from Affymetrix (available at www.affymetrix.com). In detail, cDNA synthesis was performed with a starting amount of 1-2 µg total RNA using the One-cycle cDNA synthesis kit (Affymetrix) following the Affymetrix standard protocol. Double stranded cDNA and cRNA was purified with the GeneChip sample cleanup module. Synthesis of biotinlabeled cRNA was performed using the IVT labeling kit from Affymetrix, followed by cleanup and fragmentation. After 16 h of hybridization at 45°C the arrays were washed, stained (Fluidics Station 450) and laser scanned (Affymetrix GC scanner 3000) following the Affymetrix manual. The array images were visually checked for hybridization irregularities. The average probe array signals were scaled to a target signal of 500 by using the GeneChip operating software (GCOS).
CCL3 and CCL4 protein expression in CLL-NLC co-cultures
CLL cells from 20 different patients (10 ZAP-70
+ and 10 ZAP-70 -) were placed in longterm cultures for generation of NLC, as detailed in the section "RNA isolation from CLL B cells before and after NLC co-culture" above. Supernatant samples were obtained at 2, 7, and 14 days of co-culture and assayed for CCL3 and CCL4 protein concentrations by ELISA. The patients' characteristics are displayed in the supplement section in Table   5 . 
Results
Gene expression response of CLL cells after co-culture with NLC.
We observed a relatively homogenous gene expression response of CLL cells after coculture with NLC. Table 1 displays the ten genes that were most highly up-regulated by NLC co-culture, based on at least 3-fold upregulation in at least six of the paired specimens and the overall mean upregulation in all samples. Figure 1A displays the corresponding heatmaps that illustrate the top ten up-and down-regulated genes in CLL cells after NLC co-culture relative to the baseline expression immediately after isolation from the PB. As outlined in Table 1 , the top ten genes induced by NLC co-culture are the CC chemokine CCL4, the B cell maturation antigen BCMA (TNFRSF17), early growth response protein 3 gene (EGR3), the CC chemokine CCL3, phosphoserine aminotransferase 1 (PSAT1), N-myc proto-oncogene (MYCN), early growth response protein 2 gene (EGR2), the uncharacterized gene sequence KIAA0101, Kynurenine 3-hydroxylase (KMO) and the Fc receptor-like 5 gene (FCRL5). Because of the high-level expression and because CCL3 and CCL4 have not previously been studied in CLL, we focused in our subsequent studies on these two chemokines. 
Induction of CCL3 and CCL4 correlates with ZAP-70 expression of the CLL cells
High-levels of CCL3 and CCL4 protein expression in supernatants from CLL-NLC cocultures
To determine whether our observation of CCL3 and CCL4 gene expression by microarray analysis is associated with an increased production and secretion of the respective proteins, we assayed supernatants from CLL cells placed in long-term cultures with outgrowth of NLC for CCL3 and CCL4 protein by ELISA. After 2 days of culture ( Figure 2 ) the CCL3 and CCL4 levels generally were low with higher levels and more heterogeneity in case of CCL4 (Fig 2C) . In contrast, we detected high levels of both chemokines after 7 and 14 days of culture, which coincided with the outgrowth of NLC. We reported earlier that NLC can be observed in CLL PBMC cultures as early as 3-4 days after culture initiation and the number of NLC plateaus after 7 days 3 . Figure 2 illustrates the kinetics and variability of CCL3 and CCL4 protein expression in supernatants of CLL cells from 20 different patients, illustrating the mean CCL3 and CCL4 levels at the different time points (Fig. 2A) and the individual patients' protein levels for CCL3 (Fig. 2B) and CCL4 (Fig. 2C) Tables 1 and 2 . CLL-NLC co-cultures from ZAP-70 + patients generally displayed higher levels of CCL3 (Fig. 3A) and CCL4 (Fig. 3B ) than ZAP-70 -patients.
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These differences, however, were not statistically significant (see Tab. 3,4 in the supplements).
Anti-IgM stimulation protects CLL cells from undergoing apoptosis
Self-or auto-antigens can continuously stimulate the B cell receptor on CLL cells, which, along with other signals from the microenvironment, appears to be critical for promoting CLL cell survival and growth 
IgM stimulation induces CCL3 and CCL4 protein secretion by CLL cells
Here we incubated CLL cells with increasing concentrations of anti-IgM and tested CLL supernatants after 24 h for CCL3 and CCL4 protein by ELISA. As displayed in Figure 5 , incubation of CLL cells for 24 hours with anti-IgM induced a dose-dependent induction of CCL3 and CCL4 between 0.5 and 10 µg/ml of anti-IgM, which reached a plateau at concentrations > than 10 µg/ml. CLL samples in medium alone or supplemented with anti-CD40 did not show any significant levels of CCL3 or CCL4 (see suppl. Tables 6,7) .
Time course of CCL3 and CCL4 protein secretion by CLL cells in response to BCR stimulation
In this experiment, we stimulated CLL cells for various times with 15 µg/mL of anti-IgM and determined CCL3 and CCL4 protein levels in the CLL supernatants at the indicated time points (Figure 6 ). The first increases in CCL3 and CCL4 levels in the supernatants were detected 2 hours after initiation of the cultures, and the levels continuously increased over the following hours up to the 24 h time point ( Figure 5 ). After the 24 h time point, CCL3 and CCL4 levels plateaued, suggesting that the optimal response was reached at 24 h.
The Syk inhibitor R406 inhibits CCL3 and CCL4 secretion in CLL cell co-cultures with NLC
Incubation of CLL cells with the specific Syk inhibitor R406 almost completely abrogated the induction of CCL3 and CCL4 secretion by CLL cells in co-cultures with NLC. R406 at 24h and at 48h significantly reduced the detectable CCL3 and CCL4 levels in supernatants from CLL-NLC co-cultures (p<0.05, n=4), as displayed in Fig. 7, suggesting that the induction of CCL3 and CCL4 secretion in CLL-NLC co-cultures is Syk-dependent and therefore could involve the BCR.
Increased levels of CCL3 and CCL4 in blood plasma from CLL patients
CLL cells may produce CCL3 and CCL4 in response to BCR stimulation (or other stimuli in the microenvironment) in vivo, and consequently elevated levels of these chemokines in CLL patients would be expected. Therefore, we tested blood plasma samples from CLL patients and healthy volunteers for CCL3 and CCL4 protein by ELISA. In CLL patients, the mean CCL3 blood plasma level was 47.2 ± 7 ng/ml (mean ± SEM, n = 67), compared to 20.5 ± 0.3 ng/ml (mean ± SEM, n = 9) in healthy controls. The mean CCL4 blood plasma level was 107.7 ± 29 ng/ml (mean ± SEM, n = 67) in CLL patients, only.
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However, the differences between plasma levels in CLL patients and controls did not reach statistical significance. CCL3 and CCL4 levels were higher in the plasma of CLL patients that had adverse prognostic features, in particularly a beta-2 microglobulin of > 4 mg/dl, a nonmutated status of the IgVH genes, or > 20% CD38 + CLL cells (data not shown).
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From
Discussion
Even though in the last few years increasing emphasis has been placed on exploring the tumor microenvironment as a potential therapeutic target, we currently are faced with difficulties finding suitable methods to dissect the complex cellular and molecular interactions between tumor cells and the host. In this study, we co-cultured
CLL cells and NLC to model interactions between CLL cells and CD68 + NLC in vivo.
Despite the limitation that an in vitro model is never going to be able to fully recapitulate . In Boyden chamber chemotaxis assays, CCL3 and CCL4 are potent chemoattractants for monocytes 46 and lymphocytes 47, 48 , even though the activity of these chemokines on distinct T cell subsets remains controversial 43 . Compared to CXCL12 (SDF-1), CCL3 and CCL4 are more potent chemoattractants, i.e. they require lower concentrations for maximal activity (between 1 and 10 ng/ml) 47, 48 . CCL3 signals through the chemokine receptors CCR1 and CCR5, whereas CCL4 signals only through the CCR5 chemokine receptor For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From in NLC co-cultures (Fig. 1B, suppl. Fig. 1) . We also noticed a trend for higher levels of CCL3 and CCL4 protein in supernatants from ZAP-70 + CLL-NLC co-cultures (Fig. 3) , which, however, did not reach statistical significance. This set of data suggests that ZAP-70 labels CLL cases that are more BCR-responsive, which in turn can respond to BCR stimulation with a more pronounced CCL3 and CCL4 response. On the other hand, the lack of significance when correlating ZAP-70 and CCL3/CCL4 protein induction by anti-IgM indicates that ZAP-70 may not be directly involved, and signals for CCL3/CCL4
could be transduced through other BCR signaling components, such as Syk, rather than ZAP-70, as suggested by our data using the Syk inhibitor R406.
In the context of our finding that BCR stimulation with anti-IgM induces CCL3/CCL4 secretion (Fig. 5,6 ), it is tempting to speculate that CCL3 and CCL4 induction in NLC co-cultures may be a consequence of CLL cell activation through the BCR in response to antigen(s) presented by NLC. This hypothesis is strengthened by our finding that R406, a specific Syk inhibitor, significantly inhibited the induction of CCL3 and CCL4 protein secretion by CLL cells in CLL-NCL co-cultures (Fig. 7) .
Because . As such, it is tempting to speculate that co-culture with NLC induces a similar activation/differentiation response in CLL cells, leading to the BCMA induction that we observed after NLC co-culture (Table 1, Figure1) .
Collectively, our data demonstrate 
